Summary
This Form 8-K filing by Gilead Sciences, Inc. (GILD) on April 19, 2005, primarily serves to report the company's earnings for the first quarter ended March 31, 2005. The company issued a press release detailing these results, which is attached as an exhibit. Gilead's management utilizes non-GAAP financial measures to better understand operational performance and believes these are useful for investors. For the first quarter of 2005, there were no non-GAAP adjustments, meaning the reported results reflect GAAP measures. However, for the first quarter of 2004, an adjustment was made to exclude a $20.6 million fair value gain related to Eyetech Pharmaceuticals, Inc. warrants, allowing for a clearer view of core business trends.
Key Highlights
- 1Gilead Sciences announced its first quarter 2005 financial results on April 19, 2005.
- 2The announcement was made via a press release filed as Exhibit 99.1 to the 8-K.
- 3Management uses non-GAAP financial measures to assess comparative operating performance and for investor insight.
- 4For the first quarter of 2005, no non-GAAP adjustments were made to the reported earnings.
- 5In the first quarter of 2004, a $20.6 million fair value gain on Eyetech Pharmaceuticals warrants was excluded from non-GAAP results.
- 6The exclusion of the Eyetech warrant gain in Q1 2004 was to provide a better understanding of Gilead's core business trends.
- 7The filing indicates that the information presented is not deemed 'filed' for Section 18 purposes and will not be incorporated by reference into other SEC filings.
Frequently Asked Questions
The primary purpose of this Form 8-K is to report Gilead Sciences' financial results for the first quarter ended March 31, 2005, as announced in a press release filed as an exhibit.
No, according to the filing, there were no non-GAAP financial measure adjustments for the first quarter of 2005. The reported results reflect standard GAAP measures.
In the first quarter of 2004, Gilead excluded a $20.6 million fair value gain related to its Eyetech Pharmaceuticals, Inc. warrants. This adjustment was made to present a clearer picture of the company's core business performance by removing an unusual event.
The filing explicitly states that the information contained within this Form 8-K and its exhibits shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into other filings.